Genzyme, a Cambridge unit of French drug maker Sanofi SA, reported the publication of encouraging results from studies of Lemtrada, its drug candidate for treating multiple sclerosis.

Results were published in the online edition of the medical journal Lancet. Lemtrada is being reviewed by European regulators. At some point, Genzyme plans to seek Food and Drug Administration approval.

The studies published in Lancet were chaired by Alastair Compston, a professor of neurology at the UK’s University of Cambridge. A quote from Compston was included in the Genzyme press release.

Lemtrada has the potential to “become a transformative therapy amongst the various MS treatment options that are currently available,” he said.

In a statement, Genzyme chief executive David Meeker added: “Genzyme set a new standard by comparing Lemtrada exclusively to an approved treatment in all of our studies. Publication of these findings by the Lancet highlights the importance of these results to the MS community.”